Literature DB >> 26838894

Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent.

Ratchapol Jenjob1, Na Kun2, Jung Yeon Ghee3, Zheyu Shen4, Xiaoxia Wu4, Steve K Cho5, Don Haeng Lee6, Su-Geun Yang7.   

Abstract

In this study, we prepared macromolecular MR T1 contrast agent: pullulan-conjugated Gd diethylene triamine pentaacetate (Gd-DTPA-Pullulan) and estimated residual free Gd(3+), chelation stability in competition with metal ions, plasma and tissue pharmacokinetics, and abdominal MR contrast on rats. Residual free Gd(3+) in Gd-DTPA-Pullulan was measured using colorimetric spectroscopy. The transmetalation of Gd(3+) incubated with Ca(2+) was performed by using a dialysis membrane (MWCO 100-500 Da) and investigated by ICP-OES. The plasma concentration profiles of Gd-DTPA-Pullulan were estimated after intravenous injection at a dose 0.1 mmol/kg of Gd. The coronal-plane abdominal images of normal rats were observed by MR imaging. The content of free Gd(3+), the toxic residual form, was less than 0.01%. Chelation stability of Gd-DTPA-Pullulan was estimated, and only 0.2% and 0.00045% of Gd(3+) were released from Gd-DTPA-Pullulan after 2h incubation with Ca(2+) and Fe(2+), respectively. Gd-DTPA-Pullulan displayed the extended plasma half-life (t1/2,α=0.43 h, t1/2,β=2.32 h), much longer than 0.11h and 0.79 h of Gd-EOB-DTPA. Abdominal MR imaging showed Gd-DTPA-Pullulan maintained initial MR contrast for 30 min. The extended plasma half-life of Gd-DTPA-Pullulan probably allows the prolonged MR acquisition time in clinic with enhanced MR contrast.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chelation stability; Extended blood circulation; Gadolinium-DTPA; Nephrogenic fibrosis; Transmetalation

Mesh:

Substances:

Year:  2016        PMID: 26838894     DOI: 10.1016/j.msec.2016.01.008

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  2 in total

Review 1.  Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.

Authors:  Andrew B Satterlee; Leaf Huang
Journal:  Theranostics       Date:  2016-04-27       Impact factor: 11.556

Review 2.  Recent nanotheranostics applications for cancer therapy and diagnosis: A review.

Authors:  Fahimeh Aminolroayaei; Daryoush Shahbazi-Gahrouei; Saghar Shahbazi-Gahrouei; Naser Rasouli
Journal:  IET Nanobiotechnol       Date:  2021-02-14       Impact factor: 2.050

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.